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CliniCal presentation
A 77-year-old female presented to our cancer assessment 
unit with worsening exertional shortness of breath. Phys-
ical examination of the chest was unremarkable; however, 
she was hypoxic, with pulse-oximetry measurements of 
84% on 2L of oxygen per minute. The rest of her obser-
vations were stable. She had a history of metastatic breast 
cancer treated with letrozole (hormone therapy) and meta-
static high-grade serous ovarian carcinoma for which she 
had received six cycles of carboplatin chemotherapy. 1 
month earlier a routine CT staging examination had shown 
stable malignant disease, but it also found new bilateral 
lower lobe pulmonary emboli when compared to previous 
imaging (Figures 1a, b, 2a and b) and thrombosis of the left 
common femoral vein. She was managed with once daily 
therapeutic-dose LMWH (dalteparin).
DiagnostiC iMaging anD laBoratory 
investigations
On admission, a repeat CT thorax, abdomen and pelvis 
showed progression of the previously identified pulmonary 
emboli, with new thrombi seen within the left and right 
main pulmonary arteries (Figure  1c), but with no radio-
logical features to suggest right heart strain. New mural 
hypodensities were also identified in the thoracic and upper 
abdominal aorta in keeping with extensive acute non-oc-
clusive mural thrombi (Figure 2c). Overall, CT imaging was 
strongly suggestive of a prothrombotic state, despite the 
patient receiving therapeutic-dose dalteparin.
The staging CT examinations were set up to opacity the 
thoracic aorta whilst the CTPA studies  focussed on the 
enhancement of the pulmonary arterial tree. In both cases, 
the pulmonary arterial tree and aorta became well-opaci-
fied (despite the different CT protocols) and this was likely 
due to a combination of the patient’s circulatory status, 
contrast volume and injection rate, as well as the speed of 
the CT scanner.
On her acute admission, the patient’s platelet count was 
29 × 109 l–1 (reference 160–370 × 109 l–1), having been 
normal 3 weeks previously (468 × 109 l–1) (Figure 3). The 
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aBstraCt
Heparin-induced thrombocytopaenia (HIT) is a life and limb-threatening acquired autoimmune complication of hepa-
rin-based treatment, characterised by thrombocytopaenia and thrombosis. We present a case of a 77-year-old female with 
concomitant metastatic ovarian and breast cancer who presented to our institution with worsening shortness of breath. She 
had been diagnosed with acute pulmonary embolism 1 month earlier that was treated with therapeutic low molecular weight 
heparin (LMWH). In view of her worsening symptoms, CT imaging was performed. This demonstrated significant progression 
of the bilateral pulmonary emboli and new mural thrombosis of the thoracic aorta, despite being compliant with therapeutic 
anticoagulation. She had also developed thrombocytopaenia since commencing LMWH, which raised the clinical suspicion 
of HIT syndrome. The HIT pre-test probability score was intermediate and LMWH was immediately discontinued pending 
further investigation. She was commenced on rivaroxaban, a direct oral anticoagulant, and her platelet count soon recovered. 
Laboratory testing was strongly positive on both immunological and functional assays, thus confirming a diagnosis of HIT 
syndrome. A repeat CT scan 3 weeks later showed a reduction in the overall thrombus load. Whilst venous thrombosis is 
observed in as many as half of patients with HIT, arterial thrombosis is a far less common event. Furthermore, arterial involve-
ment usually affects the distal vessels with significant atherosclerotic burden and typically presents as acute limb ischaemia 
or ischaemic stroke. Aortic thrombosis, as in this case, is a rare complication of HIT syndrome.
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remainder of her blood test results were stable (Table 1). A blood 
film showed some platelet clumping and fibrin stranding, none-
theless multiple repeat platelet count measurements confirmed a 
genuine thrombocytopaenia.
Her “4Ts” HIT score (a scoring system that estimates the pre-test 
probability of HIT), was intermediate at 4.1 Subsequent immu-
nological HIT screening was strongly positive for immuno-
globulin G anti-PF4-heparin antibodies and functional testing 
(Heparin-Induced Activation Test) was also positive, confirming 
the diagnosis of HIT. 
DiFFerential Diagnoses
The broad differential diagnoses of her thrombocytopaenia 
included sepsis, chemotherapy-induced bone marrow suppres-
sion, metastatic infiltration of the bone marrow, drug-induced 
or immune thrombocytopaenic purpura, haematinic-deficiency 
and HIT. Additional causes of thrombocytopenia such as liver 
disease, hypersplenism, microangiopathic haemolysis (e.g. 
disseminated intavasicular coagulopathy, thrombotic thrombo-
cytopenic purpura and haemolytic uraemic syndrome) and B12/
folate deficiencies were considered, but deemed less likely.
In this case, chemotherapy-induced bone marrow suppression 
was less likely since the last cycle of chemotherapy had been 
administered 6 weeks prior to this admission and the patient had 
sustained a normal platelet count throughout her treatment. This 
new thrombocytopaenia, in the context of active LMWH therapy 
and progressive pulmonary and aortic  thrombosis, triggered a 
suspicion of HIT.
A prothrombotic malignancy-related cause for the patient’s 
progressive arterial and venous thrombosis had been considered, 
but the worsening venous and new arterial thrombi following 
the administration of low molecular weight heparin treatment is 
considered a very rare entity in the context of malignancy. This 
again pointed to HIT being a more likely cause and this diag-
nosis was confirmed by immunological and functional testing 
for HIT, with platelet counts improving once heparin treatment 
was discontinued.
treatMent anD outCoMe
As soon as a diagnosis of HIT was suspected, dalteparin was 
immediately discontinued and the patient was commenced on 
rivaroxaban, a direct oral anticoagulant. Anti-cancer therapy was 
also withheld. She remained oxygen-dependent, but clinically 
well, and her platelet count normalised after 5 days (Figure 3). 
She was discharged with home oxygen and 5 weeks later her 
platelet count remained stable. A CTPA 3 weeks after leaving 
hospital showed a reduction in the overall thrombus burden 
Figure 1. (a) Coronal CT image 2 months prior to admission showing no evidence of thrombosis in the thoracic aorta. (b) Staging 
CT 1 month prior to admission showing no evidence of thrombosis in the thoracic aorta. (c) Coronal CT image  at the time of 
admission showing acute mural nonocclusive thoracic aortic thrombus (white arrow, pulmonary emboli; black arrow, aortic throm-
bosis). (d) Coronal CT image  3 weeks after commencement of rivaroxaban showing moderate reduction in aortic thrombosis and 
significant reduction of embolic burden  (white arrow, pulmonary emboli; black arrow, aortic thrombosis).
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within the aorta and bilateral lower lobe pulmonary arteries 
(Figures 1d and 2d).
DisCussion
HIT is an immune-mediated therapeutic complication of hepa-
rin-based drugs that carries significant morbidity and mortality.2 
The hallmark of this condition is the development of thrombo-
cytopaenia with a marked pro-thrombotic tendency following 
the commencement of heparin. Two different types of HIT are 
recognised:
•	 HIT Type I results from the direct action of heparin on 
platelets leading to platelet aggregation.3 This reaction occurs 
within the first three days of heparin administration, is 
short-lived, and rarely clinically significant.3 The associated 
thrombocytopaenia tends to be mild (100–150 × 109 l–1), 
resolves spontaneously and there is no associated increase in 
risk of thrombosis.3,4
•	 HIT Type II is an antibody-driven immune reaction in response 
to heparin administration, which typically occurs 4–14 days 
after exposure to heparin.4 This results in a significant fall in 
platelet count (usually >50% of baseline) and an increased risk 
of both venous and arterial thrombosis.4 The rest of this report 
will focus on this HIT type.
Development of anti-platelet factor 4 (PF4) antibodies is a 
central mechanism in the pathophysiology of HIT. PF4 is a 
pro-coagulant protein contained within the alpha granules of 
megakaryocytes and plays a role in coagulation and inflamma-
tion.4 Additionally, PF4 can neutralise the effects of heparin.5 In 
HIT, immunoglobulin G autoantibodies form against heparin–
PF4 immune complexes that are present on the platelet surface.4 
This stimulates platelets to secrete pro-coagulant microparticles 
which, in turn, have downstream effects on driving thrombin 
activation and induction of other inflammatory cell lines, such 
as monocytes.3,4 The result of this immune-mediated activation 
is a hypercoagulable state, which can precipitate catastrophic 
thrombosis.4 Simultaneously, the activated platelets are removed 
by macrophages in the reticuloendothelial system, causing the 
thrombocytopaenia present in HIT.5
The incidence of HIT varies considerably depending on patient 
and drug-related factors and may be as high as 5%.4 HIT is 
more common in patients treated with unfractionated heparin 
Figure 2. (a) Coronal CT image 2 months prior to admission showing no evidence of thrombosis in the pulmonary vasculature. 
(b) Staging CT 1 month prior to admission showing bilateral pulmonary emboli but patent main pulmonary arteries. (c) Coronal 
CT image at the time of admission showing new extensive pulmonary emboli within the main pulmonary arteries bilaterally and 
new aortic thrombosis (white arrow, pulmonary emboli; black arrow, aortic thrombosis). (d) Coronal CT image  3 weeks after 
commencement of rivaroxaban showing reduction in volume of thrombus within main pulmonary arteries and aorta (white arrow, 
pulmonary emboli; black arrow, aortic thrombosis).
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compared with LMWH.6 The risk is also higher if therapeutic 
doses are administered.7 Additionally, the observed incidence of 
HIT is higher in both female and surgical patients.2
As many as 55% of HIT patients will develop venous throm-
bosis, most commonly presenting as deep venous thrombosis 
or pulmonary embolism.8 The risk of arterial thrombosis is 
also elevated and ranges from 7 to 14%.5 Arterial thrombosis 
tends to occur in vessels with a significant degree of athero-
sclerosis, leading to limb ischaemia, myocardial infarction or 
stroke.4 Widespread aortic thrombosis involving the thoracic 
aorta, as described in our case, is an uncommon finding 
in an anatomically normal aorta and is associated with the 
pro-thrombotic state seen in malignancies or specific clotting 
factor deficiencies.9 Very rarely, a primary malignancy of 
great vessels, such as aortic angiosarcoma, can also present 
with aortic occlusive disease.10 Aortic thrombosis as a direct 
complication of HIT is even more rare  and has previously 
been reported in patients who underwent surgical procedures, 
such as aortic root replacement or insertion of an automatic 
cardioverter–defibrillator.11,12
Other presentations of HIT include skin necrosis at the site of 
heparin injection, limb gangrene, central venous thrombosis 
or spinal ischaemia.5 Bleeding complications are rare in HIT 
despite thrombocytopaenia, and current evidence does not 
support platelet transfusion due to a markedly elevated risk of 
thrombosis.5
Figure 3. Serum platelet count recorded before, during and after the patient’s admission (x109/l)
Table 1. Blood test results on admission
White cell count 6.5 (3.6–10.5 x 109 l–1) Sodium 136 (133–146 mmol l−1)
Haemoglobin 90 (118–158 g l−1) Potassium 4.4 (3.5–5.3 mmol l−1)
Platelet count 29 (160–370 x 109 l–1) Urea 9.8 (2.5–7.8 mmol l−1)
Mean platelet volume 12.6 (fl) Creatinine 119 (44–97 μmol l−1)
Lymphocyte count 1.20 (1.10–4.00 x 109 l–1) Adjusted calcium 2.31 (2.20–2.60 mmol l−1)
Basophil count 0.02 (0.00–0.20 x 109 l–1) Phosphate 0.94 (0.80–1.50 mmol l−1)
Eosinophil count 0.14 (0.02–0.50 x 109 l–1) Magnesium 0.73 (0.70–1.00 mmol l−1)
Monocyte count 0.34 (0.10–0.90 x 109 l–1) Alkaline phosphatase 82 (30–130 U l−1)
Neutrophil count 4.67 (1.50–7.70 x  109 l–1) Albumin 32 (35–50 g l−1)
CRP 21 (0–6 mg l−1) Alanine transaminase 23 (7–40 U l−1)
Lactate 1.3 (0.6–1.4 mmol l−1) Total bilirubin 5 (0–20 μmol l−1)
eGFR 38 (ml–1 min–1 1.73 m2) Glucose 7.5 (3.5–5.3 mmol l−1)
GFR, glomerular filtration rate;
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unfractionated heparin or LMWH. Additionally, HIT should 
be suspected in patients who present with thrombosis and have 
been exposed to heparin in the last 100 days.2 HIT cannot be 
confirmed based solely on laboratory testing and the diagnosis of 
HIT is reached by combining specific clinical criteria with posi-
tive laboratory testing.
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other causes of thrombocytopaenia.1 Serological testing should 
be performed in patients with at least a moderate clinical prob-
ability of HIT.2
The most widely available laboratory test used to confirm HIT 
is the ELISA heparin/platelet factor immunoassay, which is very 
sensitive (99%), but has a high false-positive rate, limiting its 
utility in low risk patients.13 Functional washed platelet assays, 
such as serotonin release assay or heparin induced aggregation 
assays have a better specificity, but are only available in specialist 
centres and thus can cause unacceptable delay in treatment.4 In 
our patient we used the Acustar Assay (IL, Werfen, Warrington 
UK) for screening and the HIPA test performed at the University 
of Greifswald, Germany for confirmation.
In patients with a high probability of HIT, all forms of heparin, 
including heparin flushes, should be discontinued immediately. 
The pro-thrombotic state continues after cessation of heparin 
therapy due to circulating anti-PF4 antibodies and an alterna-
tive non-heparin-based anticoagulant should be commenced 
to counteract this effect.4 Agents used for the treatment of 
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bivalirudin or danaparoid.4 Direct oral anticoagulants are also 
considered safe and effective in the treatment of HIT.14 Warfarin 
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contraindicated in patients with HIT, due to small amounts of 
heparin being present in certain prothrombin complex concen-
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Untreated, HIT with evidence of thrombosis carries a mortality 
rate of up to 30%, which can be significantly reduced with prompt 
recognition and appropriate interventions.3 Platelet count 
usually recovers within 1 week after withdrawal of heparin and 
anti-PF4 antibodies typically become negative after 3–4 months.2 
However, all patients who have experienced HIT in the past are 
at a higher risk of developing the complication again, thus future 
exposure to heparin-based treatments should be avoided.2
learning points
1. HIT is an immune-mediated complication of treatment 
with heparin-based therapies, characterised by 
thrombocytopaenia and thrombosis.
2. HIT must always be considered in the differential 
diagnosis for an apparent pro-thrombotic state seen on 
CT imaging.
3. Extensive aortic thrombosis in HIT, as presented in our 
case, illustrates a rare complication of this potentially life-
threatening condition.
4. Direct oral anticoagulants are seemingly a safe and 
effective treatment choice in HIT.
5. This case highlights the importance of regular platelet 
count monitoring in patients receiving heparin therapy.
Consent
Written informed consent was obtained from the patient for 
publication of this case report, including accompanying images.
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